Radioimmunotherapy of solid tumors: Searching for the right target

Hong Song, George Sgouros

Research output: Contribution to journalArticlepeer-review


Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.

Original languageEnglish (US)
Pages (from-to)26-44
Number of pages19
JournalCurrent Drug Delivery
Issue number1
StatePublished - 2011
Externally publishedYes


  • Antigen
  • Radioimmunotherapy
  • Radiolabeled antibody
  • Solid tumor

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Radioimmunotherapy of solid tumors: Searching for the right target'. Together they form a unique fingerprint.

Cite this